ASUBIO PHARMA CO., LTD.

2010/02/08	Announcement of Approval Application in Japan for Manufacturing and Marketing of SUN Y7017 (Memantine) for the Treatment of Alzheimer’s Type Dementia
2008/07/16	Asubio Pharma’s Inherited Metabolic Disease Agent Biopten Receives Approval for Additional Indication
2007/12/17	Asubio Pharma's Congenital Metabolic Abnormalities Agent Biopten Approved by U.S. Food and Drug Administration for Treatment of BH4 Responsive Hyperphenylalaninemia
2004/11/24	Daiichi Suntory Pharma Entered into License Agreement with BioMarin Pharmaceutical Inc. (USA) for A Congenital Metabolic Abnormalities Agent BIOPTEN (sapropterin hydrochloride)
2004/03/23	Daiichi Suntory Pharma Entered into License Agreement with Replidyne, Inc.( USA ) for Anti-bacterial Agent Faropenem Daloxate (penem-type antibiotic)
2003/06/02	Daiichi Suntory Pharma Co., Ltd., out-licenses Acute Heart Failure drug to Fujisawa Health Care, Inc.
2003/02/18	Daiichi Suntory Pharmaceutical Co., Ltd., Zeria Pharmaceutical and Daiichi Pharmaceutical, Inc agree for the sales license of hANP injection 1000 (for treatment of Acute Heart Failure).
2003/01/06	Daiichi Suntory Pharma Co., Ltd. begins operations.
2002/07/30	Suntory Limited and Daiichi Pharmaceutical Inc. agree to establish a new Pharmaceutical Company by separating Suntory's Pharmaceutical Division.